Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Video Presentations



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


3P Biopharmaceuticals will participate in a major European Project aiming to develop a universal influenza virus vaccine.

3P Biopharmaceuticals will participate in the European research project FLUTCORE, financed by the European Union 7th Framework Programme (FP7). The consortium is comprised of several prestigious companies and research centers specialized in influenza virus research.

3P BiopharmaceuticalsThe European consortium will be led by iQur Ltd., which is a biotech company based in London, whose research into the tandem core™ vaccine platform forms the basis of the science behind the project. Their vaccine platform has been shown to generate powerful immune responses to several pathogens and this consortium will optimize their influenza candidate vaccine for use in the clinical setting.

Currently, flu vaccines are seasonal and need to be renewed on a yearly base to be effective. Therefore, the development of a universal vaccine that does not require annual modification, and that is as effective for new virus strains as for existing ones, is considered a priority for the European Union. Furthermore, existing influenza vaccines are manufactured in fertilized chicken eggs so the incorporation of recombinant technology, used in the iQur process, constitutes an important competitive advantage. 

The other members of the consortium include Leeds University and University College of London Hospital from UK, CRP Santé from Luxemburg, the Latvijas Medicinal centre from Lituania and Institut Catala de la Salut from Spain.

Within the context of this project, 3P will be responsible for producing high quality vaccine material suitable for both for preclinical assays in animals and for Phase I clinical trial.

“iQur is excited to be leading such an illustrious consortium and delighted that 3P Pharmaceuticals has decided to participate. The inclusion of a major manufacturer of vaccines is vital since the production of clinical trial material to the highest safety standards is an absolute requirement for the success of the project”, states Mike Whelan, R&D Director of iQur. Additionally, Dámaso Molero, General Manager of 3P Biopharmaceuticals, comments that this agreement will allow 3P, “to position themselves  in the highly technically demanding European market  together with strategic Companies of recognized prestige“.

3P Biopharmaceuticals is a Biotech CMO (Contract Manufacturing Organization) based in Pamplona, specialized in the manufacturing of novel biologic drugs as vaccines or monoclonal antibodies as well as Biosimilars (highly similar biologic drugs to the ones in the market).

3P is involved together with its customers in very early phase of development, preclinical assays, and clinical assays until commercial phases.

The FLUTCORE project will constitute a great opportunity for 3P to work with top international technology partners contributing to a public health issue of great significance at both  European and international level.


more about 3P Pharmaceuticals


more news from 3P Biopharmaceuticals



Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners


Exhibitions & Events